On the other hand, Dong et al. reported that serum IGF-II level was correlated with extrahepatic metastases in HCC patients [48]; Xion et al. observed that the increase of IGF-II level in serum appeared to be associated with the occurrence of metastatic HCC after TACE and chemotherapy [49]; Sayer et al. found that high IGF-II expression was an independent predictor of poor survival in patients with epithelial ovarian cancer [50]. This evidence concerns the gene IGF2 and hepatocellular carcinoma.